Benefits
Fast-onset energy and focus
Dynamine® produces noticeable energy, mental clarity, and focus within 15–30 minutes — faster than caffeine (30–60 min) and much faster than TeaCrine® (45–90 min). This rapid onset makes it ideal as an immediate pre-workout primer or acute cognitive booster, filling the gap before caffeine reaches peak plasma concentration.
No cardiovascular side effects
Unlike caffeine, Dynamine® does not significantly elevate heart rate or blood pressure at clinical doses (100–200 mg). Safety studies confirm no adverse hemodynamic effects — enabling use by caffeine-sensitive individuals and those who want mental energy benefits without cardiovascular stimulation.
Caffeine synergy and half-life extension
A landmark pharmacokinetic study confirmed Dynamine® extends caffeine's half-life approximately 2-fold and increases caffeine's area under the curve — meaning caffeine stays active longer and at higher concentrations when combined with Dynamine®. This allows lower caffeine doses to deliver stronger, more sustained effects, reducing caffeine-related side effects while improving performance.
Mood elevation and motivation
Dynamine® modulates dopaminergic signaling pathways, producing mood elevation, motivation enhancement, and feelings of well-being. Combined with adenosine receptor antagonism, this produces a motivational state that enhances both physical training and cognitive work performance without the anxiety associated with high-dose caffeine.
Mechanism of action
Adenosine receptor antagonism and dopamine modulation
Methylliberine blocks adenosine A1 and A2A receptors — the same primary mechanism as caffeine — preventing adenosine-driven fatigue signaling and maintaining dopaminergic tone. Unlike caffeine, methylliberine appears to have greater selectivity for dopamine D2 receptor modulation, contributing to its mood-enhancing and motivational effects without the anxiogenic side effects mediated by adenosine A2A blockade in amygdala circuits.
Clinical trials
Randomized, double-blind, placebo-controlled safety study of methylliberine (Dynamine®, 100 mg or 150 mg/day) alone and in combination with TeaCrine® (theacrine, 50 mg) in healthy adults over 8 weeks. Outcomes: clinical safety markers (hematology, blood chemistry, lipids, blood pressure, heart rate, ECG). (VanDusseldorp et al. 2020, J Diet Suppl)
Healthy adults. 8-week safety study.
Dynamine® alone and combined with TeaCrine® showed no adverse effects on heart rate, blood pressure, ECG parameters, or standard hematological/biochemical markers vs placebo. Generally well-tolerated. Note: this is primarily a safety trial — does not establish efficacy claims.
Pharmacokinetic study (Compound Solutions) examining the interaction between Dynamine® and caffeine in vivo. Note: full peer-reviewed publication for this specific PK trial may be limited in PubMed.
25 healthy men and women (33.5 ± 10.7 yr; 13 women, 12 men). Double-blind, randomized, within-subject crossover trial; 100 mg methylliberine (Dynamine™) vs placebo for 3 days. On day 4, fourth dose taken in lab; testing at baseline and 1, 2, 3 hours post-ingestion. Stroop, Trail Making Test-B (TMT-B), and validated VAS for energy/mood/concentration. NCT06048640. Funded by Compound Solutions.
Methylliberine had NO significant effect on objective cognitive function (Stroop, TMT-B vs placebo, p>0.05) — placebo and Dynamine improved similarly with practice. However, Dynamine significantly improved subjective ratings of concentration (+15.3% at 3h vs PLA), motivation (+15.8% at 3h), and mood (+9.8 to 16.4% across 1-3h, all p<0.05) and sustained these effects longer than placebo. Sex-specific finding: women (lower body weight, higher mg/kg) showed greater energy and sustained energy gains at 1h and 3h with Dynamine vs placebo. No vital sign elevations; no adverse events. Distinguishes Dynamine from caffeine in not raising BP. Half-life ~1.5 hr. Foundational independent-Dynamine clinical trial (most prior trials combined Dynamine with caffeine + theacrine).